Compare CNX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | IMVT |
|---|---|---|
| Founded | 1860 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | 1999 | N/A |
| Metric | CNX | IMVT |
|---|---|---|
| Price | $35.97 | $26.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $34.50 | $29.13 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $1,930,542,000.00 | N/A |
| Revenue This Year | $49.64 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | ★ 40.99 | N/A |
| 52 Week Low | $27.00 | $12.72 |
| 52 Week High | $42.13 | $27.80 |
| Indicator | CNX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 53.28 |
| Support Level | $34.81 | $25.58 |
| Resistance Level | $36.66 | $27.37 |
| Average True Range (ATR) | 1.10 | 1.18 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 54.30 | 45.48 |
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.